HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon Anew Clinical, Cellu-Sculpt Drive Q3 Skin Care Sales Growth

This article was originally published in The Rose Sheet

Executive Summary

Avon's U.S. skin care business advanced 22% in the third quarter, boosted in part by the strong debut of Anew Clinical, President and Chief Operating Officer Susan Kropf said during an Oct. 28 analyst call

You may also be interested in...



Avon guidance

Q4 sales expected to grow 13% in dollars, and be up "high single digits" excluding the impact of foreign exchange, Avon announces Dec. 8 in guidance revision. Performance will be fueled by 16% jump in beauty product sales and 9% increase in the number of active representatives, direct-seller states. Avon also expects earnings to be $1.03-$1.04 per share, "with the upside driven by a gain of approximately $.05 per share from a tax settlement expected to be finalized this month," firm says. U.S. sales will be up low-to-mid single digits, lower than originally anticipated due in part to weak fragrance promotions. Teen brand Mark expected to contribute 1% to overall U.S. sales growth. Full year earnings will be around $2.72 per share, versus earlier estimates of $2.65-$2.70 (1"The Rose Sheet" Nov. 3, 2003, p. 6)...

Avon guidance

Q4 sales expected to grow 13% in dollars, and be up "high single digits" excluding the impact of foreign exchange, Avon announces Dec. 8 in guidance revision. Performance will be fueled by 16% jump in beauty product sales and 9% increase in the number of active representatives, direct-seller states. Avon also expects earnings to be $1.03-$1.04 per share, "with the upside driven by a gain of approximately $.05 per share from a tax settlement expected to be finalized this month," firm says. U.S. sales will be up low-to-mid single digits, lower than originally anticipated due in part to weak fragrance promotions. Teen brand Mark expected to contribute 1% to overall U.S. sales growth. Full year earnings will be around $2.72 per share, versus earlier estimates of $2.65-$2.70 (1"The Rose Sheet" Nov. 3, 2003, p. 6)...

Anew Clinical Offers Collagen, Elastin, Hydro-Protein Benefits, Avon Says

Avon's Anew Clinical Line and Wrinkle Corrector will bow in September as the flagship product in a new anti-aging skin care range, the direct-seller stated

Related Content

UsernamePublicRestriction

Register

RS011626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel